Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy

Basit Öğe Kaydı
dc.contributor.authorBoyali, Osman
dc.contributor.authorKabatas, Serdar
dc.contributor.authorCivelek, Erdinc
dc.contributor.authorOzdemir, Omer
dc.contributor.authorBahar-Ozdemir, Yeliz
dc.contributor.authorKaplan, Necati
dc.contributor.authorSavrunlu, Eyup Can
dc.date.accessioned2024-05-19T14:39:55Z
dc.date.available2024-05-19T14:39:55Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBACKGROUND Cerebral palsy (CP) describes a group of disorders affecting movement, balance, and posture. Disturbances in motor functions constitute the main body of CP symptoms. These symptoms surface in early childhood and patients are affected for the rest of their lives. Currently, treatment involves various pharmacotherapies for different types of CP, including antiepileptics for epilepsy and Botox A for focal spasticity. However, none of these methods can provide full symptom relief. This has prompted researchers to look for new treatment modalities, one of which is mesenchymal stem cell therapy (MSCT). Despite being a promising tool and offering a wide array of possibilities, mesenchymal stem cells (MSCs) still need to be investigated for their efficacy and safety. AIM To analyze the efficacy and safety of MSCT in CP patients. METHODS Our sample consists of four CP patients who cannot stand or walk without external support. All of these cases received allogeneic MSCT six times as 1 x 10(6)/kg intrathecally, intravenously, and intramuscularly using umbilical cord-derived MSCs (UC-MSC). We monitored and assessed the patients pre- and post-treatment using the Wee Functional Independence Measure (WeeFIM), Gross Motor Function Classification System (GMFCS), and Manual Ability Classification Scale (MACS) instruments. We utilized the Modified Ashworth Scale (MAS) to measure spasticity. RESULTS We found significant improvements in MAS scores after the intervention on both sides. Two months: Right chi(2) = 4000, P = 0.046, left chi(2) = 4000, P = 0.046; four months: Right chi(2 )= 4000, P = 0.046, left chi(2) = 4000, P = 0.046; 12 months: Right chi(2) = 4000, P = 0.046, left chi(2) = 4000, P = 0.046. However, there was no significant difference in motor functions based on WeeFIM results (P > 0.05). GMFCS and MACS scores differed significantly at 12 months after the intervention (P = 0.046, P = 0.046). Finally, there was no significant change in cognitive functions (P > 0.05). CONCLUSION In light of our findings, we believe that UC-MSC therapy has a positive effect on spasticity, and it partially improves motor functions.en_US
dc.identifier.doi10.12998/wjcc.v12.i9.1585
dc.identifier.issn2307-8960
dc.identifier.issue9en_US
dc.identifier.pmid38576742en_US
dc.identifier.urihttps://doi.org10.12998/wjcc.v12.i9.1585
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4872
dc.identifier.volume12en_US
dc.identifier.wosWOS:001198191300020en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBaishideng Publishing Group Incen_US
dc.relation.ispartofWorld Journal of Clinical Casesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCerebral Palsyen_US
dc.subjectMesenchymal Stem Cellen_US
dc.subjectTransplantationen_US
dc.subjectWharton's Jellyen_US
dc.subjectMuscle Spasticityen_US
dc.titleAllogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu